The development will be based on PeptiDream’s proprietary drug discovery platform, PDPS (Peptide Discovery Platform System), and JSR’s extensive knowledge of affinity separation technology.
Selexis SA and KBI Biopharma, Inc. have announced a new collaboration with ZyVersa Therapeutics to advance development of ZyVersa’s lead inflammasome inhibitor, IC 100, for the treatment of multi...
CrownBio will market a set of new, highly characterized breast cancer models alongside their industry leading collection of more than 2500 PDX models (HuPrime®).
Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.
Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform™, Aids OSE Immunotherapeutics Candidates’ Advancement into Clinic
Paper in Biotechnology and Bioengineering describes faster and more efficient technology for isolation of high-production CHO cell lines for use in manufacturing biologics
2 of 3
Receive JSR Life Sciences news on your RSS reader.